ArticleFrontiers in oncology2026
Survival outcomes and relapse patterns in high-risk metastatic neuroblastoma treated with radiotherapy-only consolidation in a resource-limited setting: a retrospective study from a lower-middle-income country.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-risk metastatic neuroblastoma (HR-MNB) requires intensive multimodal therapy for durable remission. In many low- and middle-income countries (LMICs), access to autologous stem cell transplantation (ASCT) and maintenance immunotherapy remains limited. This study evaluated survival outcomes and relapse patterns among patients with HR-MNB treated with radiotherapy-only consolidation after achieving a complete or near-complete response to induction chemotherapy in Iraq. Methods: We conducted a retrospective cohort study of children with HR-MNB treated between December 2023 and March 2024 at a national radiotherapy center. Eligible patients received standard induction chemotherapy and consolidation radiotherapy with curative intent, without ASCT. Relapse-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier methods. Relapse patterns were classified as local, distant, new-site, or combined failures. Subgroup analyses examined associations between survival outcomes and radiotherapy dose, age, and metastasis sites. Results: Twenty-five patients (median age, 48 months) were included. The median RFS from diagnosis was 18 months (95% confidence interval (CI), 14.4-21.6), and the median OS was 20.1 months (95% CI, 16.2-23.9). From radiotherapy initiation, the median RFS and OS were 5.8 and 11.4 months, respectively. Relapse occurred in 84% of patients, most frequently at new anatomical sites (56%). Subgroup analyses revealed no significant differences in survival based on radiotherapy dose or baseline characteristics. Conclusions: Radiotherapy-only consolidation following induction chemotherapy provided limited systemic disease control, reflected in early relapses and modest survival. These findings highlight the urgent need to expand access to ASCT, immunotherapy, and integrated care pathways to improve outcomes for HR-MNB in LMICs. Reporting real-world data from resource-constrained settings contributes essential evidence to guide equitable neuroblastoma treatment strategies globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.